{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-025587","form_type":"8-K","ticker":"TEM","cik":"0001717115","company_name":"Tempus AI, Inc.","filed_at":"2025-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.571568+00:00","generated_at":"2026-05-26T06:02:37.850033+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Tempus AI Q4 revenue $200.7M (+35.8% YoY); guides FY25 revenue ~$1.24B, Adj. EBITDA ~$5M","bullets":["Q4 revenue $200.7M (+35.8% YoY); Genomics $120.4M, Data $80.2M. Gross profit $122.1M (+49.7%).","FY24 revenue $693.4M (+30.4%); net loss $705.8M (incl. $547.7M stock comp); Adj. EBITDA loss $104.7M.","Closed Ambry Genetics acquisition Feb 3, 2025; combined FY25 revenue guidance ~$1.24B (+79% YoY).","Expects FY25 Adj. EBITDA ~$5M (improvement of ~$110M over FY24).","CMS reimbursement for Tempus ECG-AF algorithm at $138/test; xT CDx granted ADLT status with $4,500 reimbursement."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-025587","json":"https://secwatch.observer/filing/0000950170-25-025587.json","markdown":"https://secwatch.observer/filing/0000950170-25-025587.md","text":"https://secwatch.observer/filing/0000950170-25-025587.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1717115/000095017025025587/0000950170-25-025587-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1717115/000095017025025587/tem-20250224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T06:02:37.850033+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}